pyrroles has been researched along with Hypertriglyceridemia in 62 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (20.97) | 18.2507 |
| 2000's | 32 (51.61) | 29.6817 |
| 2010's | 15 (24.19) | 24.3611 |
| 2020's | 2 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Cruz-López, P; González, JG; Parmar, D; Rodriguez-Gutierrez, R; Shaikh, F | 1 |
| Bhansali, A; Bhansali, S; Hawkins, M; Jain, N; Kaur, S; Kurpad, AV; Rastogi, A; Sharma, A | 1 |
| Cha, DH; Cho, EJ; Chung, WJ; Hong, SJ; Hong, TJ; Jeon, DS; Jeon, DW; Jeong, JC; Jeong, JO; Jeong, MH; Kim, CJ; Kim, KS; Kim, MH; Kim, SK; Kwan, J; Lee, HY; Lee, JH; Lee, JW; Park, CG; Shin, J; Woo, JS; Youn, HJ | 1 |
| Dhull, P; Kumar, KV; Patnaik, SK; Upreti, V | 1 |
| Brown, E; Crane, HM; Delaney, JA; Eron, JJ; Hunt, PW; Kahn, JO; Kitahata, MM; Liu, W; Mathews, WC; Mugavero, MJ; Muñoz, MA; Napravnik, S; Saag, MS; Willig, JH | 1 |
| Bhansali, A; Jani, RH; Jariwala, G; Jha, P; Joshi, S; Mukhopadhyay, S; Pai, V | 1 |
| Deshpande, A; Jani, RH; Joshi, S; Toshniwal, H | 1 |
| Golčić, M; Petković, M | 1 |
| Kelwade, J; Nagesh, VS; Sethi, BK; Vaseem, A | 1 |
| Saegusa, Y; Shiragami, M; Takahashi, T; Takimoto, Y | 1 |
| Beach, RA; McQueen, M; Wismer, J | 1 |
| Banga, JD; Dallinga-Thie, GM; Dullaart, RP; Huisman, MV; Kappelle, PJ; Sluiter, WJ; Zwang, L | 1 |
| Cole, RP | 1 |
| Bai, L; Hu, M; Huang, XS; Zhang, Q; Zhao, SP; Zhao, W | 2 |
| Bernátová, I; Dlugosová, K; Okruhlicová, L; Slezák, J; Sotníková, R; Weismann, P | 1 |
| Whayne, TF | 1 |
| Bays, HE; Carter, RN; Doyle, RT; Maki, KC; McKenney, J; Stein, E | 1 |
| Alegret, M; Ađalsteisson, GS; Laguna, JC; Merlos, M; Rebollo, A; Roglans, N; Vilà, L | 1 |
| Bacova, B; Barancik, M; Knezl, V; Kolenova, L; Mitasikova, M; Navarova, J; Radosinska, J; Tribulova, N; Weismann, P | 1 |
| Ballantyne, CM; Jones, PH; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Thakker, KM | 1 |
| Dlugošová, K; Javorková, V; Mézešová, L; Mitašíková, M; Okruhlicová, L; Tribulová, N; Vlkovičová, J; Vrbjar, N | 1 |
| Chu, Q; Dunlop, D; Hao, D; Jacobs, CD; Leighl, N; Lopez-Anaya, A; Middleton, G; Ramlau, R; Rodon, J; Rowinsky, EK; Takimoto, CH; Wakelee, HA; Zatloukal, P | 1 |
| Nordøy, A | 1 |
| Barrett, PH; Laubach, E; Parhofer, KG | 1 |
| Funatsu, T; Kakuta, H; Miyata, K; Noguchi, M; Suzuki, M; Takasu, T | 1 |
| Bonet, R; Jorba, O; Ordóñez-Llanos, J; Pérez, A; Wägner, AM | 1 |
| Empen, K; Geiss, HC; Lehrke, M; Otto, C; Parhofer, KG; Schwandt, P | 1 |
| Berk-Planken, II; Bootsma, AH; Dallinga-Thie, GM; Jansen, H | 1 |
| Chan, WB; Chow, CC; Ko, GT; Ma, RC; Osaki, R; So, WY; Yeung, VT | 1 |
| Fushimi, H | 1 |
| Assaloni, R; Ceriello, A; Da Ros, R; Esposito, K; Giugliano, D; Maier, A; Piconi, L; Quagliaro, L | 1 |
| Bulut, D; Bulut-Streich, N; Graf, C; Hanefeld, C; Mügge, A; Spiecker, M | 1 |
| Nosaka, S; Ueki, M; Ushiroyama, T | 1 |
| Cariolou, M; Christidis, DS; Elisaf, MS; Ganotakis, ES; Kakafika, AI; Liberopoulos, EN; Mikhailidis, DP; Miltiadous, GA | 1 |
| Chen, Y; Kohno, M; Kosaka, H; Mizukawa, M; Ohmori, K; Shinomiya, K; Yoshida, J; Zeng, Y; Zhang, L | 1 |
| Gandhi, SK; Ghali, JK; Hassman, DR; Insull, W; Miller, E; Y As, JW | 1 |
| Ishisaka, DY; Karalis, DG; Luo, D; Ntanios, F; Wun, CC | 1 |
| Paraskevas, KI | 1 |
| Bergeron, J; Couture, P; Deshaies, Y; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ | 1 |
| Bergeron, J; Couture, P; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ | 1 |
| Bakker-Arkema, RG; Black, DM; Brown, WV; Davidson, MH; Davignon, J; Goldstein, RJ; Isaacsohn, JL; Keilson, LM; Miller, VT; Shurzinske, LJ; Weiss, SR | 1 |
| Abe, Y; Ballantyne, CM; Dunn, K; Gotto, AM; Hackman, A; Insull, W; Pownall, H; Smith, L | 1 |
| Krause, BR; Newton, RS | 1 |
| Alaupovic, P; Black, DM; Heinonen, T; Shurzinske, L | 1 |
| Connor, WE; Duell, PB; Illingworth, DR | 1 |
| Lane, M; Laskarzewski, P; Stein, EA | 1 |
| Black, DM; Kafonek, S; Koren, M; McCormick, LS; McKenney, JM; Weiss, S | 1 |
| Malinowski, JM | 1 |
| Lee, TH | 1 |
| Jonkers, GH | 1 |
| Cheung, R; Mutus, B; Tannous, M; Vignini, A | 1 |
| de Man, FH; Mohrschladt, MF; Smelt, AH; Stoeken, DJ; Sturk, A; Westendorp, RG; Weverling-Rijnsburger, AW | 1 |
| Bakker-Arkema, R; Black, D; Brown, WV; Innis-Whitehouse, W; Le, NA; Li, X | 1 |
| Blauw, GJ; de Man, FH; Jukema, JW; Smelt, AH; van der Laarse, A; Weverling-Rijnsburger, AW | 1 |
| Adams-Huet, B; Balis, D; Devaraj, S; Grundy, SM; Jialal, I; Stein, D | 1 |
| Breuer, HW | 1 |
| Crook, MA; Reynolds, TM; Wierzbicki, AS | 1 |
| Funatsu, T; Goto, M; Ida, M; Kakuta, H; Miyata, K; Nishijima, S; Suzuki, M; Tanaka, H; Yasuda, S | 1 |
| Adeli, K; Cheung, RC; Mangaloglu, L; Pontrelli, L; Taghibiglou, C; Van Iderstine, SC | 1 |
6 review(s) available for pyrroles and Hypertriglyceridemia
| Article | Year |
|---|---|
Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diet; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Exercise; Fatty Acids, Omega-3; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2002 |
[Treatment of cerebral infarction patients with IGT].
Topics: Antidepressive Agents; Antipyrine; Atorvastatin; Cerebral Infarction; Edaravone; Free Radical Scavengers; Glucose Intolerance; Heptanoic Acids; Humans; Hyperglycemia; Hypertension; Hypertriglyceridemia; Insulin Resistance; Pyrroles; Secondary Prevention; Thrombolytic Therapy | 2005 |
Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Chronic Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Kidney Diseases; Lipids; Peritoneal Dialysis; Pyrroles; Risk Assessment; Risk Factors; Survival Rate; Treatment Outcome | 2008 |
Comparison of statins in hypertriglyceridemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 1998 |
Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Pyrroles | 1998 |
Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Topics: Atorvastatin; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Niacin; Pyridines; Pyrroles; Risk Factors; Triglycerides | 2001 |
27 trial(s) available for pyrroles and Hypertriglyceridemia
| Article | Year |
|---|---|
Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial.
Topics: Adult; Double-Blind Method; Fenofibrate; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Phenylpropionates; Pyrroles; Triglycerides | 2022 |
Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial.
Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Endpoint Determination; Female; Glycated Hemoglobin; Humans; Hypertriglyceridemia; Insulin Resistance; Lipids; Male; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles | 2019 |
Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ω-3 Fatty Acids 4 g Fixed-dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-week, Multicenter, Random
Topics: Aged; Atorvastatin; Double-Blind Method; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Pyrroles; Treatment Outcome; Triglycerides | 2021 |
A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRES
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Fasting; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Patient Safety; Phenylpropionates; Prospective Studies; Pyrroles; Risk Reduction Behavior; Treatment Failure; Treatment Outcome; Triglycerides | 2014 |
A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy.
Topics: Adolescent; Adult; Aged; Cholesterol; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Hypertriglyceridemia; Insulin; Lipoproteins; Male; Middle Aged; Phenylpropionates; Prospective Studies; Pyrroles | 2016 |
Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin.
Topics: Analysis of Variance; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Prescriptions; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Male; Middle Aged; Pyrroles; Treatment Outcome; United States | 2010 |
Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2011 |
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Atorvastatin; Bexarotene; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Interactions; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Pyrroles; Tetrahydronaphthalenes; Treatment Outcome | 2012 |
Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Blood Flow Velocity; Cholesterol; Diterpenes; Heptanoic Acids; Humans; Hypertriglyceridemia; Lipoproteins; Postprandial Period; Pyrroles; Retinyl Esters; Triglycerides; Vitamin A | 2003 |
Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Gemfibrozil; Heptanoic Acids; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Treatment Outcome | 2003 |
Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.
Topics: Angiotensin-Converting Enzyme Inhibitors; Apolipoprotein C-III; Apolipoproteins B; Apolipoproteins C; Atorvastatin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypertriglyceridemia; Lipoproteins, HDL; Male; Middle Aged; Pyrroles; Triglycerides | 2004 |
A comparative study of atorvastatin and simvastatin as monotherapy for mixed hyperlipidaemia in Type 2 diabetic patients.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2004 |
Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Biphenyl Compounds; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperglycemia; Hypertriglyceridemia; Inflammation; Irbesartan; Male; Middle Aged; Oxidative Stress; Postprandial Period; Pyrroles; Tetrazoles; Treatment Outcome | 2005 |
Short-term effects of low-dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic, hypertriglyceridemic women.
Topics: Adult; Atorvastatin; Blood Coagulation; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Female; Fibrinolysis; Gonadal Steroid Hormones; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Inflammation; Lipids; Lipoproteins; Malondialdehyde; Middle Aged; Plasminogen Activator Inhibitor 1; Postmenopause; Premenopause; Prospective Studies; Pyrroles; Time Factors; Tissue Plasminogen Activator; Triglycerides | 2006 |
Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Disease; Creatinine; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Managed Care Programs; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2007 |
Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Lipids; Male; Middle Aged; Pyrroles; Triglycerides | 2007 |
Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Topics: Anticholesteremic Agents; Apolipoprotein B-100; Apolipoprotein B-48; Atorvastatin; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Fenofibrate; Heptanoic Acids; Humans; Hypertriglyceridemia; Kinetics; Leucine; Male; Middle Aged; Pyrroles; Triglycerides | 2008 |
Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Biomarkers; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Inflammation; Lipids; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pyrroles | 2008 |
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Linear Models; Lipoproteins; Male; Middle Aged; Pyrroles; Triglycerides | 1996 |
Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
Topics: Adolescent; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles | 1997 |
A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Male; Middle Aged; Niacin; Pyrroles; Treatment Outcome; Triglycerides; United States | 1998 |
[Fluvastatin in a comparative study. Are there substance-specific differences between various CSE-inhibitors?].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Indoles; Pyrroles | 1999 |
Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Blood Proteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Enzyme Induction; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Male; Middle Aged; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidation-Reduction; Pyrroles; Treatment Outcome; Triglycerides; Tyrosine; Vasodilation | 1999 |
Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Bezafibrate; Cross-Over Studies; Cytokines; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Reference Values | 2000 |
Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
Topics: Anticholesteremic Agents; Apolipoproteins; Apolipoproteins B; Apolipoproteins E; Atorvastatin; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, VLDL; Chromatography, High Pressure Liquid; Double-Blind Method; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Lipids; Lipoproteins, HDL; Particle Size; Pyrroles; Triglycerides | 2000 |
Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation: reversal after lipid-lowering therapy by atorvastatin.
Topics: Acetylcholine; Acute Disease; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Chronic Disease; Endothelium, Vascular; Free Radical Scavengers; Heptanoic Acids; Humans; Hypertriglyceridemia; Injections, Intravenous; Male; Middle Aged; Nitroprusside; Pyrroles; Serotonin; Triglycerides; Vasodilation; Vasodilator Agents | 2000 |
Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Interleukin-6; Male; Middle Aged; Pravastatin; Pyrroles; Receptors, Interleukin-6; Simvastatin; Treatment Outcome; Triglycerides | 2001 |
29 other study(ies) available for pyrroles and Hypertriglyceridemia
| Article | Year |
|---|---|
An unusual cause of delayed puberty: Berardinelli- Seip syndrome.
Topics: Administration, Cutaneous; Adolescent; Atorvastatin; Combined Modality Therapy; Diet, Fat-Restricted; Drug Therapy, Combination; Estrogens; Exercise Therapy; Female; Fenofibrate; Fish Oils; Heptanoic Acids; Humans; Hypertension, Portal; Hypertriglyceridemia; Insulin; Insulin Resistance; Lipodystrophy, Congenital Generalized; Pioglitazone; Propranolol; Puberty, Delayed; Pyrroles; Thiazolidinediones; Treatment Outcome | 2012 |
Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care.
Topics: Adult; Alabama; Atorvastatin; California; CD4-Positive T-Lymphocytes; Cohort Studies; Comparative Effectiveness Research; Drug Interactions; Female; Fenofibrate; Fish Oils; Gemfibrozil; Heptanoic Acids; HIV Infections; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; North Carolina; Practice Guidelines as Topic; Pyrroles; Retrospective Studies; San Francisco; Treatment Outcome; Triglycerides; Washington | 2013 |
Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer - A new potential biomarker?
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cholesterol; Ferritins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypothyroidism; Indazoles; Indoles; Iron; Kidney Neoplasms; Lipids; Metabolome; Models, Theoretical; Neoplasm Metastasis; Prognosis; Pyrimidines; Pyrroles; Sirolimus; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Triglycerides | 2016 |
Unique Interaction of Saroglitazar with Insulin.
Topics: Blood Glucose; Diabetes Mellitus; Drug Interactions; Female; Humans; Hypertriglyceridemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Middle Aged; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles | 2015 |
Pharmacoeconomic analysis of hypertriglyceridemia treatment at medical institutions.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Cost-Benefit Analysis; Economics, Pharmaceutical; Fenofibrate; Health Facilities; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Pyrroles; Triglycerides | 2008 |
Novel management of isotretinoin-induced hypertriglyceridemia in an adolescent with severe acne.
Topics: Acne Vulgaris; Adolescent; Anticholesteremic Agents; Atorvastatin; Dermatologic Agents; Female; Heptanoic Acids; Humans; Hypertriglyceridemia; Isotretinoin; Pyrroles | 2009 |
Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
Topics: Aged; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Triglycerides | 2009 |
Heparin treatment for severe hypertriglyceridemia in diabetic ketoacidosis.
Topics: Atorvastatin; Cholesterol; Diabetic Ketoacidosis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Omega-3; Fenofibrate; Half-Life; Heparin; Heptanoic Acids; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Infusions, Intravenous; Insulin; Male; Middle Aged; Pancreatitis, Acute Necrotizing; Pyrroles; Triglycerides | 2009 |
Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha.
Topics: Animals; Apolipoprotein A-V; Apolipoproteins; Atorvastatin; Cell Line, Tumor; Drug Synergism; Fenofibrate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Liver; Male; PPAR alpha; Pyrroles; Rats; Rats, Sprague-Dawley; Triglycerides; Up-Regulation | 2009 |
Omega-3 fatty acids and atorvastatin affect connexin 43 expression in the aorta of hereditary hypertriglyceridemic rats.
Topics: Animals; Aorta, Thoracic; Atorvastatin; Blotting, Western; Connexin 43; Endothelium, Vascular; Fatty Acids, Omega-3; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Microscopy, Electron, Transmission; Pyrroles; Rats; Rats, Inbred SHR; Rats, Wistar | 2009 |
Concerns about heparin therapy for hypertriglyceridemia.
Topics: Atorvastatin; Cholesterol; Chylomicrons; Diabetic Ketoacidosis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Omega-3; Fenofibrate; Half-Life; Heparin; Heptanoic Acids; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Infusions, Intravenous; Insulin; Male; Middle Aged; Pancreatitis, Acute Necrotizing; Pyrroles; Triglycerides | 2010 |
[Statin reduced triglyceride level via activating peroxisome proliferator activated receptor α and upregulating apolipoprotein A5 in hypertriglyceridemic rats].
Topics: Animals; Apolipoprotein A-V; Apolipoproteins; Atorvastatin; Down-Regulation; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; PPAR alpha; Pyrroles; Rats; Rats, Sprague-Dawley; Triglycerides; Up-Regulation | 2010 |
Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment.
Topics: Animals; Atorvastatin; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cyclic AMP-Dependent Protein Kinases; Dietary Carbohydrates; Disease Models, Animal; Down-Regulation; Fatty Acids; Fatty Liver; Fructokinases; Fructose; Gene Expression Regulation; Hepatitis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; I-kappa B Proteins; Inflammation Mediators; Lipid Metabolism; Liver; Male; Metallothionein; Necrosis; NF-kappa B; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; Phosphorylation; Pyrroles; Rats; Rats, Sprague-Dawley; Triglycerides | 2011 |
Omega-3 fatty acids and atorvastatin suppress ventricular fibrillation inducibility in hypertriglyceridemic rat hearts: implication of intracellular coupling protein, connexin-43.
Topics: Animals; Arrhythmias, Cardiac; Atorvastatin; Blood Pressure; Connexin 43; Fatty Acids, Omega-3; Heart Rate; Heart Ventricles; Heptanoic Acids; Hypertriglyceridemia; Myocardium; Myocytes, Cardiac; Phosphorylation; Pyrroles; Rats; Rats, Wistar; Triglycerides; Up-Regulation; Ventricular Fibrillation | 2010 |
Gender specific influence of fish oil or atorvastatin on functional properties of renal Na,K-ATPase in healthy Wistar and hypertriglyceridemic rats.
Topics: Adenosine Triphosphate; Animals; Anticholesteremic Agents; Atorvastatin; Female; Fish Oils; Heptanoic Acids; Hypertriglyceridemia; Kidney; Male; Pyrroles; Rats; Rats, Inbred Strains; Rats, Wistar; Sex Factors; Sodium-Potassium-Exchanging ATPase | 2011 |
Experimental model of postprandial hypertriglyceridemia in sucrose-fed rats and the effectiveness of atorvastatin in the model.
Topics: Animals; Area Under Curve; Atorvastatin; Dietary Fats; Emulsions; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Lipoproteins; Lipoproteins, VLDL; Male; Olive Oil; Plant Oils; Postprandial Period; Pyrroles; Rats; Rats, Sprague-Dawley; Sucrose; Triglycerides | 2003 |
Effect of atorvastatin on lipid parameters, LDL subtype distribution, hemorrheological parameters and adhesion molecule concentrations in patients with hypertriglyceridemia.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Viscosity; Cholesterol, HDL; Cholesterol, LDL; Female; Hemorheology; Heptanoic Acids; Humans; Hypertriglyceridemia; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Triglycerides | 2003 |
Comparison of endothelial function in patients with metabolic syndrome on bezafibrate or atorvastatin therapy.
Topics: Aged; Atorvastatin; Bezafibrate; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Coronary Circulation; Endothelium, Vascular; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Regional Blood Flow; Treatment Outcome; Vasodilation | 2005 |
The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
Topics: Adult; Aged; Analysis of Variance; Apolipoprotein A-I; Apolipoproteins B; Apolipoproteins E; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Gene Frequency; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Treatment Outcome; Triglycerides | 2006 |
Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes.
Topics: Adiponectin; Adipose Tissue; Animals; Anticholesteremic Agents; Atorvastatin; Chemokine CCL2; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Glucose; Heptanoic Acids; Hypertriglyceridemia; Insulin Resistance; Leptin; Myocardium; Nitric Oxide; Nitric Oxide Synthase Type III; Pravastatin; Pyrroles; Rats; Rats, Long-Evans; Rats, Mutant Strains; RNA, Messenger; Transforming Growth Factor beta1; Ventricular Dysfunction, Left | 2007 |
Levels of soluble cell adhesion molecules in patients with dyslipidemia.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cell Adhesion Molecules; Colestipol; Drug Therapy, Combination; E-Selectin; Endothelium, Vascular; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Lovastatin; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Solubility; Vascular Cell Adhesion Molecule-1 | 1996 |
Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Guinea Pigs; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Liver; Lovastatin; Male; Pyrroles; Rabbits; Rats; Rats, Sprague-Dawley; Triglycerides | 1995 |
[Effective cholesterol and triglyceride lowering with atorvastatin].
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertriglyceridemia; Pyrroles | 1996 |
Rhabdomyolysis after taking atorvastatin with gemfibrozil.
Topics: Adult; Atorvastatin; Drug Interactions; Drug Therapy, Combination; Female; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hypertriglyceridemia; Hypolipidemic Agents; Pyrroles; Rhabdomyolysis | 1998 |
After I had a heart attack and two bypass operations, I was put on Lipitor to lower my cholesterol. My cholesterol was never high--about 170-180 mg/dL. But my HDL was always low and triglycerides were somewhat high. Now my total cholesterol is 124 and my
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hypertriglyceridemia; Pyrroles | 1999 |
Tamoxifen and hypertriglyceridemia.
Topics: Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Atorvastatin; Breast Neoplasms; Clofibrate; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Middle Aged; Pyrroles; Simvastatin; Tamoxifen; Treatment Outcome | 1999 |
Usefulness of Orlistat in the treatment of severe hypertriglyceridemia.
Topics: Adult; Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Dietary Fiber; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Heptanoic Acids; Humans; Hypertriglyceridemia; Lactones; Male; Middle Aged; Niacin; Orlistat; Pyrroles; Statistics, Nonparametric; Treatment Outcome | 2002 |
Reduction in hepatic non-esterified fatty acid concentration after long-term treatment with atorvastatin lowers hepatic triglyceride synthesis and its secretion in sucrose-fed rats.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Coenzyme A Ligases; Dietary Sucrose; Disease Models, Animal; Down-Regulation; Fatty Acids, Nonesterified; Heptanoic Acids; Hypertriglyceridemia; Lipase; Lipoproteins, VLDL; Liver; Male; Oleic Acid; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Triglycerides; Tritium | 2002 |
Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic ins
Topics: Animals; Apolipoproteins B; Atorvastatin; Blood Glucose; Cells, Cultured; Cholesterol; Cricetinae; Disease Models, Animal; Fructose; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Insulin Resistance; Kinetics; Lipoproteins, VLDL; Liver; Luminescent Measurements; Mesocricetus; Phosphorylation; Pyrroles; Receptor, Insulin; Triglycerides | 2002 |